Sirnaomics Ltd

Sirnaomics operates with a negative equity position of -$9.91 million and a cash balance of $13.52 million, resulting in a liquidity risk score of low. The company's debt-to-equity ratio is -0.94, indicating a negative equity position, and its current ratio of 0.4 suggests limited short-term liquidity. The enterprise value to EBITDA ratio is -48.38, reflecting the company's unprofitable status and high valuation multiple. The company's return on equity is 1.45%, while its return on assets is -0.699%, both significantly below the industry median for biotechnology firms. These metrics highlight the company's inability to generate returns from its asset base and equity. Operating income of -$13.79 million and net income of -$14.40 million underscore the company's ongoing losses. Sirnaomics derives all its revenue from research and development activities, with no disclosed geographic diversification. The company's operations are entirely focused on clinical-stage drug development, with no commercialized products contributing to revenue. This concentration in a single business model increases exposure to clinical trial risks and regulatory delays. The company's outlook for the current fiscal year shows no revenue growth, with a net loss expected to continue. The next fiscal year is projected to maintain a similar trajectory, with no significant changes in revenue or profitability. The company's capital expenditure of -$56,000 is minimal, reflecting its reliance on external funding for operations. Sirnaomics faces low dilution risk, with no immediate filing-based flags detected. The company's shares outstanding remain unchanged at 109.72 million, and no recent equity issuance or shelf registration has been disclosed. However, the company's negative equity position and high cash burn rate may necessitate future fundraising, which could lead to dilution. Recent events include the ongoing clinical trials for STP705 and STP707, with no new product approvals or regulatory milestones reported. The company's 10-K filing highlights the risks associated with clinical development, including the potential for trial failures and regulatory hurdles. No recent earnings calls or investor presentations have been disclosed that would indicate a change in strategy or financial outlook.